Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2005-01-11
2005-01-11
Borin, Michael (Department: 1631)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S317000, C530S330000, C514S011400, C514S018700
Reexamination Certificate
active
06841533
ABSTRACT:
Novel peptides which are conformationally constrained backbone cyclized antagonists of IL-6, are disclosed. Methods for synthesizing the IL-6 antagonists are also disclosed. Furthermore, pharmaceutical compositions comprising IL-6 antagonists, and methods of using such compositions are disclosed.
REFERENCES:
patent: 3988304 (1976-10-01), Garsky
patent: 4011182 (1977-03-01), Sarantakis
patent: 4054558 (1977-10-01), Garsky
patent: 4187217 (1980-02-01), Chipens et al.
patent: 4235886 (1980-11-01), Freidinger et al.
patent: 4310518 (1982-01-01), Freidinger et al.
patent: 5210075 (1993-05-01), Scholz et al.
patent: 5364851 (1994-11-01), Joran
patent: 5371070 (1994-12-01), Koerber et al.
patent: 5420109 (1995-05-01), Suto et al.
patent: 5470942 (1995-11-01), Alexander et al.
patent: 5639455 (1997-06-01), Shimamura et al.
patent: 5770687 (1998-06-01), Hornik et al.
patent: 5874529 (1999-02-01), Gilon et al.
patent: 5883293 (1999-03-01), Gilon et al.
patent: 6051554 (2000-04-01), Hornik et al.
patent: 41 19 544 (1992-10-01), None
patent: 41 19 544 (1992-11-01), None
patent: 031 303 (1981-07-01), None
patent: 0 031 303 (1981-07-01), None
patent: 334 244 (1989-09-01), None
patent: 0 334 244 (1989-09-01), None
patent: 336 779 (1989-10-01), None
patent: 0 336 779 (1989-10-01), None
patent: 0 370 453 (1990-05-01), None
patent: 370 453 (1990-05-01), None
patent: 395 417 (1990-10-01), None
patent: 0 395 417 (1990-10-01), None
patent: 0 336 779 (1991-08-01), None
patent: 564 739 (1993-10-01), None
patent: 0 564 739 (1993-10-01), None
patent: 0 564 739 (1995-04-01), None
patent: 2 304 352 (1976-10-01), None
patent: 2411828 (1979-07-01), None
patent: 2 411 828 (1979-07-01), None
patent: WO 8901781 (1989-03-01), None
patent: WO 9200091 (1992-01-01), None
patent: WO 9222566 (1992-12-01), None
patent: WO 9301206 (1993-01-01), None
patent: WO 9411393 (1994-05-01), None
patent: WO 9501800 (1995-01-01), None
patent: WO 9513086 (1995-05-01), None
patent: WO 9533765 (1995-12-01), None
patent: WO 9709344 (1997-03-01), None
patent: WO 9713781 (1997-04-01), None
patent: WO 9748728 (1997-12-01), None
patent: WO 9804583 (1998-02-01), None
patent: WO 9965508 (1999-12-01), None
patent: WO 0072864 (2000-07-01), None
Bell et al., 1993, “Molecular biology of somatostatin receptors”,TINS16:34-38.
Brazeau et al. 1973, “Hypothalamic Polypeptide That Inhibits the Secretion of Immunoreactive Pituitary Growth Hormone”,Science179:77-79.
Buscail et al., 1995, “Inhibition of cell proliferation by the somatostatin analogue RC-160 is mediated mechanisms”,Proc. Natl.by somatostatin receptor subtypes SSTR2 and SSTR5 through differentAcad. Sci. USA92:1580-1584.
Hirano, T., 1998, “Interleukin 6 and its Receptor: Ten Years Later”, Intern. Rev. Immunol., 16:249.
Yoshizaki et al., 1998, “Therapy of Rheumatoid Arthritis by Blocking IL-6 Signal Transduction with a Humanized Anti-IL-6 Receptor Antibody”, Springer Semin. Immunopathol., 20: 247.
Kozak et al., 1997, “Sickness Behavior in Mice Deficient in Interleukin-6 During Turpentine Abscess and Influenza Pneumonitis”, American J. Physiology, 272: 2 R621.
Simpson et al., 1997, “Interleukin-6: Structure-function Relationships”, Protein Sci., 6: 929.
Xu et al., 1997, “Solution Structure of Recombinant Human Interleukin-6”, J. Mol. Biol., 268: 468.
Fourcin et al., 1996, “gp130 Transducing Receptor Cross-linking Is Sufficient to Induce Interleukin-6 Type Responses”, J. Biol. Chem., 271: 11756.
Murakamin-Mori et al., 1996, “The Soluble Form of the IL-6 Receptor (sIL-6Rα) Is a Potent Growth Factor for AIDS-associated Kaposi's sarcoma (KS) cells; the Soluble Form of gp130 is Antagonistic for sIL-6Rα-Induced AIDS-KS Cell Growth”, Int. Immunol., 8: 595.
Ogata, A., 1996, “Therapeutic Strategies of Inhibition of Interleukin-6 Mediated Multiple Myeloma Cell Growth”, Leuk. Res., 20: 303.
Sporeno et al., 1996, “Human Interleukin-6 Receptor Super-Antagonists with High Potency and Wide Spectrum on Multiple Myeloma Cells”, Blood, 87: 4510.
Toniatti et al., 1996,“Engineering Human Interleukin-6 to Obtain Variants with Strongly Enhanced Bioactivity”, The EMBO J., 15: 2726.
Halimi et al., 1995, “Epitope Peptides from Interleukin-6 Receptor Which Inhibit the Growth of Human Myeloma Cells”, Eur. Cytokin. Netw., 6: 135.
Klein et al., 1995, “Interleukin-6 in Human Multiple Myeloma”, Blood, 85:863.
Byk et al., 1992, “Building units for N-backbone cyclic peptides. 1. Synthesis of protected N-(ω-aminoalkylene)amino acids and their incorporation into dipeptide units”,J. Org. Chem.57:5687-5692.
Charpentier et al., 1989, “Synthesis and binding affinities of cyclic and related linear analogues of CCK§selective for central receptors,” J. Med. Chem, pp. 1184-1190.
Giannis et al., 1993, “Peptidomimetics for receptor ligands—discovery, development, and medical perspective,” Angew. Chem. Int. Ed. Engl. 32: 1244-1267.
Gilon et al., 1991, “Backbone Cyclization: A New Method for Conferring Conformational Constraint on Peptides”,Biopolymers31:745-750.
Gilon et al., 1992, “SAR studies of cycloseptide: effects of cyclization and charge at position 6,” Chem. Biol. Proc. Am. Pept. Symp 1th. pp. 476-477.
Greiner et al., 1994, “Synthesis of New Backbone-Cyclized Bradykinin Analogs”,Proc. Eur. Pept. Symp., 23rd, Meeting Date 1994, 289-290.
Hruby et al., 1990, “Emerging approaches in the molecular design of receptor-selective peptide ligands: conformational, topographical and dynamic considerations,” Biochem. J. 268: 249-262.
Klein, et al., 1995, “Interleukin-6 in Human Multiple Myeloma,” Blood, vol. 85, No. 4, pp. 863-872.
Krstenansky et al., 1994, “Cyclic hexapeptide antagonists of the bradykinin B2receptor: Receptor binding and solution backbone conformation”,Letters in Peptide Science1:229-234.
Lamberts, 1988, “The role of Somastatin in the regulation of anterior pituitary hormone secretion and the use of its analogs in the treatment of human pituitary tumors,” Endocrine Reviews vol. 9, No. 4, pp. 417-436.
Lamberts et al., 1990,“Somastatin-receptor imaging in the localization of endocrine tumors,” New England J. Med. 323: 1246-1249.
Lymangrover et al., 1993, “Varying the duration of A23187 administration alters its effect on adrenal steroidogenesis,” Life sciences 34:371-377.
Mosberg et al., 1983, “Bis-penicillamine enkephalins posses highly improved specificity toward δ opioid receptors,” Biochemistry 80:5871-5874.
Plotsky et al., 1985, “Patterns of growth hormone-releasing factor and somatostatin secretion into the hypophysial-portal circulation of the rat,” Science 230:461-463.
Raynor et al., 1993, “Cloned somatostatin receptors: identification of subtype-selective peptides and demonstration of high affinity binding of linear peptides,” Mol. pharmacol. 43:838-844.
Reisine et al., 1995, “Molecular biology of somatostatin receptors,” Endocrine reviews 16, 427-442.
Reubi et al., 1995, “Multiple actions of somatostatin in neoplastic disease,” TIPS 16:110-115.
Rizo et al., 1992, “Constrained peptides: Models of bioactive peptides and protein substructures,” Annu. Rev. Biochem. 61:387-418.
Rodriguez et al. 1990, “Synthesis of cyclic analogues of cholecystokinin highly selective for central receptors,” Int. J. Peptide Protein Res. 35:441-451.
Rudinger, 1976, “Characteristics of the Amino Acids as components of a peptide hormone sequence,” Peptide Hormones, Ed. J.A. Parsons, University Park Press, Baltimore, pp. 1-7.
Schumann et al., 1996, Database Caplus, DN: 130:14228. Pept. 1996, Proc. Eur. Pept. Symp., 24th (1998). Meeting Date 1996, 797-798. Editors: Ramage, Robert; Epton, Roger. Publisher: Mayflower Scientif
Hadas Eran
Hornik Vered
Borin Michael
Peptor Limited
Winston & Strawn LLP
LandOfFree
Conformationally constrained backbone cyclized interleukin-6... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Conformationally constrained backbone cyclized interleukin-6..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Conformationally constrained backbone cyclized interleukin-6... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3388399